DARE News and Press, Dare Bioscience Inc. From 09/06/22

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in a fireside chat during the H.C. Wainwright 2...

Dare Bioscience ( NASDAQ: DARE ) said that based on an interim analysis of phase 2b data for its sildenafil cream for female sexual arousal disorder, enrollment in the study will complete in Q4. Total enrollment will be 150 women. The company anticipates a top-line dat...

Study Enrollment Expected to Complete in 4Q-2022 with Approximately 150 Subjects Topline Data of Phase 2b RESPOND Study Targeted for 2Q-2023 If clinical development is successful, Sildenafil Cream, 3.6% has the potential to be the first FDA-approved FSAD treatment option...

SAN DIEGO, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it has entered into a license agreement with Hennepin Life Sciences LLC under which Daré acquired the exclusive global rig...

The following slide deck was published by Daré Bioscience, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Daré Bioscience, Inc. 2022 Q2 - Results - Earnings Call Presentation

Dare Bioscience, Inc. (DARE) Q2 2022 Earnings Conference Call August 09, 2022, 16:30 ET Company Participants Sabrina Johnson - President, CEO, Secretary & Director John A. Fair - Chief Strategy Officer Lisa Walters-Hoffert - CFO Conference Call Particip...

Dare Bioscience press release ( NASDAQ: DARE ): Q2 GAAP EPS of $0.00. Revenue of $10M. License fee revenue recognition: $10.0 million during 2Q-2022 in connection with the closing under the global license agreement with Organon to commercialize XACIATO Upon the fir...

June 30, 2022: $32.1 million in cash and cash equivalents July 2022: approximately $18.0 million in cash received subsequent to quarter-end: $10.0 million upfront license fee under global license agreement with Organon to commercialize XACIATO TM (clindamycin phosphate) vagi...

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, August 9, 2022, to review its finan...

SAN DIEGO, July 07, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and CEO, will be participating in a virtual panel discussion presented by Maxim Group LLC a...